Moleculin Biotech Reduces Warrant Exercise Price to $3.90, Boosts Equity Above $10M to Address Nasdaq Delisting

Moleculin Biotech, Inc.

Entered warrant amendment agreements on Dec 21, 2025 reducing exercise price of Series E, F, G warrants to $3.90 per share.
Amended Series E and F warrants to delete certain anti-dilution provisions and modify Black Scholes Value definition.
Received Nasdaq delisting notice on Nov 20, 2025 for non-compliance with $2.5M equity rule; appealed and hearing set for Jan 20, 2026.
Raised $6.8M from warrant exercise on Dec 9, 2025 and $1.1M from ATM facility; stockholders' equity now exceeds $10.0M.
Panel hearing for Nasdaq appeal scheduled for January 20, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Moleculin Biotech, Inc. amended Warrant Amendment with holders of the Company’s Series E warrants, Series F warrants, and Series G warrants valued at $3.90 per share (effective 2025-12-21).

Action: amendment
Counterparty: holders of the Company’s Series E warrants, Series F warrants, and Series G warrants
Value: $3.90 per share
Effective: 2025-12-21

Exact text from the filing

On December 21, 2025, Moleculin Biotech, Inc. (the “Company”) entered into separate warrant amendment agreements (collectively, the “Warrant Amendment”) with the holders of the Company’s Series E warrants (the “Series E warrants”), Series F warrants (the “Series F warrants”), and Series G warrants (the “Series G warrants,” and collectively with the Series E warrants and Series F warrants, the “Warrants”).

View on SEC.gov

117 material agreements filed in the last 30 days. Browse all material agreements →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-038478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.